Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

NCT03350672 | Completed Phase 4 Results FDA Drug

• 1 other identifier: PhiladelphiaFight
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

Pre-exposure prophylaxis (PrEP) with Truvada™ (tenofovir/emtricitabine), in which an HIV-uninfected individual at high risk for contracting HIV takes antiretroviral medications (one pill daily) to maintain blood and genital drug levels sufficient to prevent HIV-1 acquisition, has been validated in several large international trials that have included men who have sex with men and transgender women, heterosexual men and women, and people who use injection drugs, as a potential HIV-1 prevention strategy. HIV prevention interventions such as this, if adequately disseminated and implemented broadly, may help to curb new HIV infections, reduce HIV-associated morbidity and mortality, and reduce health disparities in HIV rates among the most at-risk individuals. Assuring adherence to a daily dose of PrEP is critical for effective protection against HIV infection. A urine-based test to measure PrEP medication levels in the body represents a non-invasive technique to assess adherence and ultimately improve PrEP's protective ability. TAF/FTC (Descovy™) is a new medication under study for HIV prevention to see if it is as effective as Truvada™. This study is testing whether a urine test can detect this medication in urine.

Conditions

Hiv

Keywords

HIV prevention; PrEP; Descovy

Outcome Measures

Primary Outcomes (3)

• Percentage of Urine Samples Containing TFV in Concentrations Greater Than or Equal to 1000ng/mL From the 7-dose Cohort (1b).

  Cohort 1b: To determine how long TFV is excreted in the urine in patients at steady state of TAF/FTC. Ten healthy subjects will be given seven daily doses of TAF/FTC under direct observation to ensure adherence. Morning urine samples will be collected starting the day the last is given (1 hour later) and every day thereafter for 9 days (total of 10 days). Urine samples collected from all participants were analyzed via LC-MS/MS for tenofovir concentrations.

  Daily for a maximum of 10 days

• Percent of Urine Samples Containing TFV Levels Greater Than or Equal to 1000ng/mL in the Single Dose Cohort (1a).

  To determine how long TFV is excreted in the urine in patients who have taken one dose of TAF/FTC. Ten healthy subjects will be given one dose of TAF/FTC under direct observation to ensure adherence. Morning urine samples will be collected starting the day the dose is given (1 hour later) and every day thereafter for 6 days (total of 7 days of sample collection). This will allow for the assessment of the length of time TFV can be measured in the urine after last dose is taken (the "lookback" period) in the context of inconsistent or intermittent (1 day only) adherence, as well as to determine how many days a patient has been off drug if a urine specimen has no detectable TFV.

  7 days

• Percentage of Urine Samples Containing Tenofovir at Concentrations Greater Than or Equal to 1000ng/mL (Cohort 2).

  To determine the expected urine tenofovir levels in a population of patients living with HIV on TAF-based regimens. A cross-sectional analysis of ten patients living with HIV with undetectable viral loads on a TAF-based single tablet HIV regimen will be conducted. Morning urine samples will be collected at one time point to determine urine TFV concentration in the setting of steady state dosing in HIV patients with presumably very good adherence to medication.

  1 day

Study Arms (3)

Cohort 1a

EXPERIMENTAL

Age 18 or older at the time of signed informed consent * Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP * Willing and able to independently provide written informed consent * Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test

Drug: FTC/TAF

Cohort 1b

EXPERIMENTAL

Age 18 or older at the time of signed informed consent * Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP * Willing and able to independently provide written informed consent * Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test

Drug: FTC/TAF

Cohort 2

ACTIVE COMPARATOR

* Age 18 or older at the time of signed informed consent * Willing and able to independently provide written informed consent * Last viral load \< 20 copies/mL within the last four weeks of screening * Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months * Undetectable viral load, as defined by \< 50 copies/ml, for at least 6 months

Drug: FTC/TAF

Interventions

FTC/TAF DRUG

Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.

Cohort 1a; Cohort 1b; Cohort 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 or older at the time of signed informed consent
• Not currently taking commercial Truvada for PrEP or any other investigational, oral medication for the purpose of HIV PrEP
• Willing and able to independently provide written informed consent
• Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test

You may not qualify if:

• Evidence of acute or chronic hepatitis B infection at the time of screening
• Other clinically significant acute or chronic medical condition, including severe infections requiring treatment such as tuberculosis, as determined by the study investigator
• Evidence of renal dysfunction (Creatinine Clearance \< 30 ml/min) at the time of screening; Use Cockroft-Gault equation: GFR = (140-Age in years) x (Weight in kg) / (72 x serum creatinine)
• History of bone fractures not explained by trauma
• Grade 3 laboratory abnormality on screening tests/assessments as defined by the DAIDS grading system
• Known allergy/sensitivity to the study drug or its components
• Experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
• Any other clinical condition or prior therapy that, in the opinion of the Principal Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements
• Age 18 or older at the time of signed informed consent
• Willing and able to independently provide written informed consent
• Last viral load \< 20 copies/mL within the last four weeks of screening
• Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months
• Undetectable viral load, as defined by \< 50 copies/ml, for at least 6 months
• Other clinically significant acute or chronic medical condition, including severe infections requiring treatment such as tuberculosis, as determined by the study investigator
• Evidence of renal dysfunction (Creatinine Clearance \< 30 ml/min) at the time of screening; Use Cockroft-Gault equation: GFR = (140-Age in years) x (Weight in kg) / (72 x serum creatinine)

Sponsors & Collaborators

• Philadelphia Fight: lead
• Gilead Sciences: collaborator

Study Sites (1)

Philadelphia FIGHT

Philadelphia, Pennsylvania, 19107, United States

Location

Related Publications (1)

• Lalley-Chareczko L, Hiserodt E, Moorthy G, Zuppa A, Mounzer K, Koenig H. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide. Front Pharmacol. 2020 Mar 19;11:286. doi: 10.3389/fphar.2020.00286. eCollection 2020.

  PMID: 32265700 RESULT

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Results Point of Contact

• Title: Linden Lalley-Chareczko
• Organization: Philadelphia FIGHT Community Health Centers

lchareczko@fight.org

2155258695

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: 1a) Ten healthy subjects will be given seven daily doses of TAF/FTC under direct observation to ensure adherence. 1b) Ten healthy subjects will be given one daily dose of TAF/FTC under direct observation to ensure adherence. Morning (not first morning) urine and plasma samples will be collected starting the day the dose is given (1 hr post-dose) and every day thereafter for 6 days. 2\) Ten HIV-positive patients who have had undetectable viral loads for greater than 12 weeks (and a recent undetectable viral load in the previous 4 weeks) on an antiretroviral regimen containing TAF/FTC (i.e. Genvoya™, Odefsey™, or Descovy™ in combination with another HIV medication or medications) will have one-time pre-dose urine (early morning) and plasma samples drawn for tenofovir (TFV) concentration, as well as a comprehensive metabolic panel for measurement of creatinine clearance.

Study Record Dates

• First Submitted: November 14, 2017
• First Posted: November 22, 2017
• Study Start: November 16, 2017
• Primary Completion: March 29, 2018
• Study Completion: May 1, 2018
• Last Updated: September 30, 2021
• Results First Posted: September 30, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)